83 Einträge gefunden

1. Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in Germany, Molecular diagnostics in dermatology

   1. Tizek, Linda
   2. Schuster, Barbara
   3. Gebhardt, Christoffer
   4. Reich, Kristian
   5. von Kiedrowski, Ralph
   6. Biedermann, Tilo
   7. Eyerich, Kilian

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis

   1. Simpson, Eric L
   2. Bissonnette, Robert
   3. Paller, Amy S
   4. King, Brett
   5. Silverberg, Jonathan I
   6. Reich, Kristian
   7. Thyssen, Jacob P

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis

   1. Reich, Kristian
   2. Conrad, Curdin
   3. Kristensen, Lars Erik
   4. Smith, Saxon D
   5. Puig, Luis
   6. Rich, Phoebe
   7. Sapin, Christophe

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis

   1. Reich, Kristian
   2. Baraliakos, Xenophon
   3. Coates, Laura C
   4. Elewski, Boni
   5. Bao, Weibin
   6. Kasparek, Torben
   7. Gaillez, Corine

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
5. Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?

   1. Reich, Kristian
   2. Cullen, Eva
   3. Weinberg, Mark

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
6. Generalized pustular psoriasis: overview of the status quo and results of a panel discussion

   1. Reich, Kristian
   2. Augustin, Matthias
   3. Gerdes, Sascha
   4. Ghoreschi, Kamran
   5. Kokolakis, Georgios
   6. Mößner, Rotraut
   7. Mrowietz, Ulrich

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
7. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

   1. Reich, Kristian
   2. Thyssen, Jacob P
   3. Blauvelt, Andrew
   4. Eyerich, Kilian
   5. Soong, Weily
   6. Rice, Zakiya P
   7. Hong, H Chih-Ho

   2022 - Forschungsinformationssystem des UKE
8. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials

   1. Simpson, Eric L
   2. Merola, Joseph F
   3. Silverberg, Jonathan I
   4. Reich, Kristian
   5. Warren, Richard B
   6. Staumont-Sallé, Delphine
   7. Girolomoni, Giampiero

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
9. Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis

   1. Silverberg, Jonathan I
   2. Simpson, Eric L
   3. Armstrong, April W
   4. de Bruin-Weller, Marjolein S
   5. Irvine, Alan D
   6. Reich, Kristian

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
10. Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form

    1. Blome, Christine
    2. von Stülpnagel, Catharina C
    3. Augustin, Matthias
    4. Mrowietz, Ulrich
    5. Reich, Kristian
    6. Muehlan, Holger
    7. Kirsten, Natalia

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
11. Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial

    1. Reich, Kristian
    2. Kristensen, Lars Erik
    3. Smith, Saxon D
    4. Rich, Phoebe
    5. Sapin, Christophe
    6. Leage, Soyi Liu
    7. McKenzie, Robert

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
12. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis

    1. Reich, Kristian
    2. Lio, Peter A
    3. Bissonnette, Robert
    4. Alexis, Andrew F
    5. Lebwohl, Mark G
    6. Pink, Andrew E
    7. Kabashima, Kenji

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
13. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial

    1. Augustin, Matthias
    2. Reich, Kristian
    3. Yamauchi, Paul
    4. Pinter, Andreas
    5. Bagel, Jerry
    6. Dahale, Swapnil
    7. You, Ruquan

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
14. Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO

    1. Reich, Kristian
    2. Korge, Bernhard
    3. Magnolo, Nina
    4. Manasterski, Maria
    5. Schwichtenberg, Uwe
    6. Staubach-Renz, Petra
    7. Kaiser, Stephan

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
15. Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis

    1. Conrad, Curdin
    2. Ortmann, Christine-Elke
    3. Vandemeulebroecke, Marc
    4. Kasparek, Torben
    5. Reich, Kristian

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
16. Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab

    1. Augustin, Mathias
    2. Gallo, Gaia
    3. See, Kyoungah
    4. McKean-Matthews, Missy
    5. Burge, Russel
    6. Gooderham, Melinda
    7. Reich, Kristian

    2022 - Forschungsinformationssystem des UKE
17. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)

    1. Bieber, Thomas
    2. Reich, Kristian
    3. Paul, Carle
    4. Tsunemi, Yuichiro
    5. Augustin, Matthias
    6. Lacour, Jean-Philippe
    7. Ghislain, Pierre-Dominique

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
18. Contact sensitization to essential oils:IVDK data of the years 2010-2019

    1. Geier, Johannes
    2. Schubert, Steffen
    3. Reich, Kristian
    4. Skudlik, Christoph
    5. Ballmer-Weber, Barbara
    6. Brehler, Randolf
    7. Weisshaar, Elke

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
19. Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM Study

    1. Mrowietz, Ulrich
    2. Kircik, Leon
    3. Reich, Kristian
    4. Munjal, Sagar
    5. Shenoy, Srinivas
    6. Lebwohl, Mark

    2022 - Forschungsinformationssystem des UKE
20. Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey

    1. Lebwohl, Mark
    2. Langley, Richard G
    3. Paul, Carle
    4. Puíg, Lluis
    5. Reich, Kristian
    6. van de Kerkhof, Peter
    7. Wu, Hsiuan-Lin

    2022 - Forschungsinformationssystem des UKE - frei zugänglich